Accredited Activity

Eye Connect AAO - When to Start, When to Switch, and What Dosing Strategy Should Be Used With Anti-VEGF Therapy for nAMD
Overview

This case consult with Dr Borkar and Dr Do will consider a patient with newly diagnosed vision loss. After reviewing the diagnosis, these retina specialists discuss intravitreal anti-vascular endothelial growth factor (VEGF) treatment options including the more durable anti-VEGF therapies. Approaches to selecting an agent, treatment initiation, and criteria for changing dosing intervals and switching therapies are topics discussed during review of this case. With a lack of clear guidance, clinicians are challenged to use these new agents. This case will illustrate how to incorporate the more durable anti-VEGF therapies into clinical practice and how treatment success is defined.

Target Audience

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and other eye care/healthcare professionals who treat patients with age-related macular degeneration (AMD).

Educational Provider
This activity is provided by The American Academy of Ophthalmology, with support from Paradigm Medical Communications, LLC
Supporter Acknowledgment

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Determine dosing intervals for the novel, more durable anti-VEGF therapies based on clinical trial data
Faculty & Disclosures

Faculty

Durga S. Borkar, MD, MMCi
Assistant Professor of Ophthalmology
Vitreoretinal Surgery and Diseases
Assistant Professor of Population Health Sciences
Director of Clinical Data Science
Duke University Eye Center
Durham, NC

Diana V. Do, MD
Vice Chair of Clinical Affairs
Professor of Ophthalmology
The Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA

Scientific Integrity and Disclosure of Financial Interest
The American Academy of Ophthalmology is committed to ensuring that all continuing medical education (CME) information is based on the application of research findings and the implementation of evidence-based medicine. It seeks to promote balance, objectivity and absence of commercial bias in its content. All persons in a position to control the content of this activity must disclose any and all financial interests. The Academy has mechanisms in place to resolve all conflicts of interest prior to an educational activity being delivered to the learners.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The Academy requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to The Academy’s policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. The Academy is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.

A full listing of financial disclosures can be found below. All relevant financial relationships have been mitigated.

Durga S. Borkar, MD, MMCi
Consultant/Advisor: Abbvie; Apellis Pharmaceuticals, Inc.; GENENTECH; Glaukos Corporation; Iveric Bio; ONL Therapeutics; Verana Health
Lecture Fees/Speakers’ Bureau: Iveric Bio

Diana V. Do, MD
Consultant/Advisor: Apellis Pharmaceuticals, Inc; Belite Bio; Boehringer Ingelheim; GENENTECH; Iveric Bio; Kodiak Sciences Inc; Kriya Therapeutics; Lumithera; Regeneron Pharmaceuticals Inc.
Grant Support: Lumithera

The American Academy of Ophthalmology and Paradigm staff members have no relevant financial relationships with ineligible companies to disclose.

Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.

CME Information

CME for Physicians
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement
The American Academy of Ophthalmology designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Participation
To receive a certificate of participation, participants must:

  • Follow instructions to register or log in with your professional information and complete the preassessment
  • View the online activity in its entirety
  • Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment

A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation.

For questions regarding CME credit, contact The American Academy of Ophthalmology at cme@aao.org.

There are no fees for participating in this activity.

Hardware/Software Requirements
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents

This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support
If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, The American Academy of Ophthalmology or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, The American Academy of Ophthalmology must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by The American Academy of Ophthalmology.

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by The American Academy of Ophthalmology or Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by The American Academy of Ophthalmology or Paradigm Medical Communications, LLC. The American Academy of Ophthalmology and Paradigm Medical Communications, LLC accept no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.

© American Academy of Ophthalmology 2024 except where noted. Content may not be reproduced in whole or part without the express written permission of the American Academy of Ophthalmology.

Case Consult
Release Date: June 4, 2024
Expiration Date: June 4, 2025
Time to Complete: 15 minutes
Credit: 0.25 hour

 

Credit Type: AMA PRA Category 1 Credit
Target Audience: Retina specialists and ophthalmologists